Creative Touch Permanent Makeup and Aesthetics

Omega-6 fatty acids are not a single thing, and treating them as one is where most of the confusion starts.

Linoleic acid (LA) serves a real structural role in the stratum corneum being esterified into acylceramides whose unusual molecular geometry helps maintain the lamellar lipid architecture that waterproofs the barrier. But true LA deficiency is clinically negligible in any normal diet. The minimum requirement is around 0.1–0.5% of calories; Western diets provide 6–8%. More LA beyond adequacy does not produce better barrier outcomes; the pathway is enzyme-limited, not substrate-limited.

Arachidonic acid (AA) is where omega-6’s inflammatory reputation is earned. Produced from LA in the liver and immune cells, AA feeds the COX and LOX eicosanoid pathways that drive the inflammatory skin conditions most clients want help with. The dietary culprit is primarily refined seed oils in ultra-processed foods rather than nuts, eggs, or whole food fat sources.

Then there is gamma-linolenic acid (GLA), which is actively anti-inflammatory through a pathway that bypasses AA entirely – particularly relevant for atopic dermatitis, where the enzymatic step converting LA to GLA is often impaired.

And there is a PUFA oxidation story that deserves more attention than it typically gets. LA oxidises in sebum under normal UV and ambient oxygen exposure, generating 4-hydroxynonenal (4-HNE) – a reactive aldehyde with established mechanistic links to elastin damage and fibroblast senescence. Human adipose tissue LA has increased 136% since 1959. Whether that accumulation is translating into measurable additional photoageing has not yet been quantified in longitudinal studies, but the mechanism is coherent and the substrate is undeniably there.

Omega-6 fatty acids are a family of polyunsaturated fatty acids (PUFAs) defined by a double bond at the sixth carbon from the methyl end of the chain. The family includes linoleic acid (LA), gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA), and arachidonic acid (AA) – members with different, sometimes opposing, roles in skin biology. Treating them as a single category is one of those shortcuts that travels widely precisely because it is just accurate enough in the one case (AA) that counts for most people’s experience of inflammatory skin conditions. ^[1]

Linoleic Acid: Structurally Present, Rarely Deficient

Linoleic acid (LA) is an 18-carbon omega-6 fatty acid and genuinely essential, meaning that the body cannot synthesise it. It plays a specific structural role in the stratum corneum: it is esterified into acylceramides ( Ceramide EOS and EOP), the ceramide subclass whose unusual long-chain geometry creates the molecular bridging structure that holds the lamellar lipid stacks in their tightly ordered, water-impermeable arrangement. When LA is absent from this position and oleic acid substitutes for it, the geometry changes, lamellar order breaks down, and TEWL rises. The function is real.

But here is where the marketing diverges from the biology. True LA deficiency – the kind that actually disrupts barrier function – is clinically rare to the point of being an edge case. It occurs in prolonged total parenteral nutrition without lipid supplementation, severe fat malabsorption syndromes, and extreme fat-restricted diets maintained over long periods. The minimum intake preventing deficiency is estimated at approximately 0.1–0.5% of total calories. Current Western dietary intakes sit at 6–8% of calories – ten to twenty times the minimum. LA is present in virtually every food that contains fat, including meat, eggs, dairy, nuts, seeds. Practically speaking, you would have to try extremely hard to become deficient.

This matters for how the entity is framed. A canine feeding trial by Popa and colleagues tested what happens when dietary LA is increased beyond baseline: stratum corneum LA content rose, confirming that dietary intake does modify skin lipid composition – but barrier function did not improve. ^[6] Once the minimum threshold is met, more LA does not produce better barrier outcomes. The pathway is enzyme-limited, not substrate-limited; ceramide biosynthesis does not scale up with additional linoleic acid supply.

There is also a distinction worth making between topical and dietary LA. Topically applied linoleic acid does not directly become Ceramide EOS – that requires keratinocyte uptake, systemic processing, and a multi-step enzymatic pathway. The Danby study most frequently cited to support LA in skincare enrolled 19 participants, tested forearm skin only, and examined topical application exclusively; ^[3] its findings cannot be validly extended to dietary recommendations, and even its topical conclusions come from a sample too small for confident generalisation.

Additionally, the epidermis largely lacks the Δ6 and Δ5 desaturase enzymes needed to convert LA to arachidonic acid, the pro-inflammatory downstream metabolite that gives omega-6 its reputation. LA in epidermal keratinocytes is predominantly structural, not inflammatory. ^[8]

The PUFA Oxidation Question

This is the part of the omega-6 story that receives far less attention than it deserves, and the evidence is stronger than casual wellness content acknowledges.

Polyunsaturated fatty acids are chemically vulnerable by nature. Their multiple double bonds contain unstable bis-allylic hydrogen atoms that are susceptible to abstraction by reactive oxygen species. When omega-6 PUFAs oxidise – which happens in sebum under normal ambient UV and oxygen exposure, not just under pathological conditions – they generate reactive aldehyde products including 4-hydroxynonenal (4-HNE). This is not a hypothetical: linoleic acid hydroperoxide has been directly detected in sebum from healthy volunteers under normal conditions. ^[4]

What makes 4-HNE particularly relevant to skin ageing is what it does once formed. A 2015 study published in the Journal of Investigative Dermatology demonstrated that UV-A exposure in mice produced 4-HNE forming covalent adducts with elastin, generating the hallmark structural changes of photoaging. ^[5] The intervention that prevented this was carnosine, a carbonyl scavenger that neutralises 4-HNE; its complete reversal of both the adduct formation and the photoaging features establishes causation, not just correlation. Separately, 4-HNE has been shown to induce fibroblast senescence through DNA damage response and SIRT1 downregulation – the mechanism by which senescent fibroblasts accumulate in aged skin and secrete matrix-degrading enzymes through the SASP pathway.

The implication is uncomfortable but coherent: at a time when LA in human adipose tissue has increased by 136% since 1959 – a change that tracks almost perfectly with increased seed oil consumption – there is more substrate available in skin tissue for this oxidation cascade than at any previous point in recorded history. Whether this quantitatively explains a meaningful proportion of photoaging in human populations remains to be demonstrated in longitudinal studies. But the individual mechanistic steps are each well-supported.

This is not an argument for eliminating LA. It is an argument for questioning the assumption that more LA is always better, and for preferring topical formulations that minimise free PUFA content and the oxidation products it can generate.

Arachidonic Acid: Where the Inflammatory Reputation Is Earned

Arachidonic acid (AA) is the omega-6 fatty acid where the pro-inflammatory story is genuinely accurate. AA is produced primarily in the liver and immune cells from LA through the Δ6 and Δ5 desaturase steps, incorporated into membrane phospholipids throughout the body, and released by phospholipase A₂ when inflammatory signals are triggered. COX and LOX enzymes then convert it into PGE₂ and LTB₄ – the primary pro-inflammatory lipid mediators in skin, driving vasodilation, mast cell activation, keratinocyte proliferation, and immune cell recruitment. This is the pathway that EPA competes with, and it is real and clinically significant. ^[1]

What does drive excessive AA production – and this is the specific dietary pattern the omega-6 concern is actually pointing at – is heavy consumption of refined seed oils: sunflower, safflower, corn, soybean oil used in large quantities in ultra-processed foods and cheap cooking. These deliver LA at a scale where even low systemic conversion rates produce a meaningful AA pool over time. This is the omega-6 story that matters in practice. It is not a story about nuts, seeds, eggs, or whole food fat sources.

GLA: The Anti-Inflammatory Omega-6

GLA deserves explicit treatment because it completely disrupts the simple inflammatory narrative. GLA is an 18-carbon omega-6 fatty acid found primarily in evening primrose oil and borage oil. Its pathway bypasses the pro-inflammatory branch entirely.

GLA enters the omega-6 cascade already past the Δ6 desaturase step and is rapidly elongated to DGLA. DGLA converts predominantly to PGE₁ and 15-HETrE, both anti-inflammatory mediators. Critically, 15-HETrE directly inhibits 5-LOX, blocking the conversion of AA to LTB₄. GLA supplementation produces anti-inflammatory effects through an entirely omega-6 pathway, without requiring any omega-3 at all. ^[7]

A study of 130 mild AD subjects given GLA-rich oil showed reduced TEWL and higher stratum corneum integrity at four weeks compared to control. In atopic dermatitis specifically, the Δ6 desaturase step is often impaired, meaning these patients cannot efficiently convert dietary LA to GLA themselves – supplementing GLA directly bypasses this bottleneck and delivers the DGLA/PGE₁ pathway without depending on an enzymatic step that is not working. Combined GLA plus omega-3 EPA has the strongest combined evidence for inflammatory skin conditions: GLA suppressing LTB₄ through 15-HETrE inhibition whilst EPA displaces AA from membrane phospholipids – two distinct mechanisms toward the same outcome. ^[1]

A note on evidence calibration here: the Cochrane review of oral EFA supplementation for atopic eczema found insufficient evidence to recommend its use, concluding the evidence was sparse and of uncertain quality. ^[2] Individual positive trials for GLA and combined EPA+GLA are worth knowing about; the Cochrane conclusion is also worth knowing about. Neither negates the other, they just reflect where the evidence is at this point.

The Ratio, Revisited

The omega-6/omega-3 ratio is a proxy for the AA:EPA competition in membrane phospholipids, and that competition is real. But as a dietary target, the ratio obscures where the actual problem sits.

The omega-6 excess that drives the AA pool to pro-inflammatory levels is not coming from nuts, eggs, meat, or dairy. It is coming from the refined seed oils used in bulk in ultra-processed foods and cheap restaurant cooking – sunflower, safflower, corn, soybean – which deliver LA in concentrated quantities that a whole food diet simply does not approach. Anyone eating a broadly whole food diet is unlikely to have an LA problem regardless of what their theoretical ratio looks like, because the volume is not there.

The ratio argument is therefore most usefully aimed at processed food consumption, not at dietary fat broadly. The practical response: reduce refined seed oil exposure, ensure adequate EPA+DHA intake, and the ratio takes care of itself.